Skip to main content

Advertisement

SpringerLink
Log in

Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

There is limited guidance on intravenous dosing of unfractionated heparin in obese patients. The purpose of this study was to determine the efficacy and safety of a standard unfractionated heparin (UFH) protocol in obese patients based on total body weight (TBW) or adjusted body weight (ABW) to reach two consecutive therapeutic anti-Xa levels. This was a retrospective observational cohort study conducted in a large academic medical center. Adults received a standard UFH protocol between January 1, 2013 to December 31, 2015. Inclusion criteria included age ≥ 18 years of age, weight ≥ 100 kg with a BMI ≥ 30 kg/m2, and received intravenous UFH. Patients were excluded if they received an alternative UFH protocol, received < 24 h of the standard UFH protocol, or had inadequate compliance to protocol. Out of the 131 patients included, 109 patients reached two consecutive therapeutic UFH levels within 96 h. The average time to two consecutive therapeutic UFH levels was 29.4 h and 27.6 h in patients dosed by TBW and ABW, respectively (95% CI − 4.63 to 8.11; P = 0.93). Safety outcomes included major bleeding, overt bleeding, or death events between patients dosed by TBW compared to ABW, (p = 0.61, p = 1.0, p = 1.0, respectively). Dosing intravenous UFH based on TBW or ABW resulted in similar times to therapeutic anti-Xa levels and safety outcomes. The data provided suggests using either TBW or ABW in obese patients is as effective and safe to use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pfizer. Heparin Sodium Injection package insert. New York, NY; 2016

  2. Centers for Disease Control and Prevention. Defining adult overweight and obesity (April 2017). https://www.cdc.gov/obesity/adult/defining.html (accessed 2019 Feb 1)

  3. Hales CM, Carroll MD, Fryar CD, Ogden CL (2017) Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief. 1–8

  4. Holst AG, Jensen G, Prescott E (2010) Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 121:1896–1903

    Article  Google Scholar 

  5. Floroff CK, Palm NM, Steinberg DH, Powers ES, Wiggins BS (2017) Higher maximum doses and infusion rate compared with standard unfractionated UFH therapy are associated with adequate anticoagulation without increased bleeding in both obese and non-obese patients with cardiovascular indication. Pharmacotherapy 37(4):393–400

    Article  CAS  Google Scholar 

  6. Estes JW (1980) Clinical pharmacokinetics of heparin. Clin Pharmacokinet 5:204–220

    Article  CAS  Google Scholar 

  7. Schaefer DC, Hufnagle J, Williams L (1996) Rapid heparin anticoagulation: use of a weight-based nomogram. Am Fam Physician 54:2517–2521

    CAS  PubMed  Google Scholar 

  8. Riney JN, Hollands J, Smith JR, Deal EN (2010) Identifying optimal initial infusion rates for unfractionated UFH in morbidly obese patients. Ann Pharmacother 44:1141–1151

    Article  CAS  Google Scholar 

  9. Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS (2011) Activated partial thromboplastin time versus anti-factor Xa UFH assay in monitoring unfractionated UFH by continuous intravenous infusion. Ann Pharmacother 45(7–8):861–868

    Article  CAS  Google Scholar 

  10. Rosenberg AF, Zumberg M, Taylor L, Leclaire A, Harris N (2010) The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy. J Pharm Pract 23(3):210–216

    Article  Google Scholar 

  11. Garcia D, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants- antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. Chest 141:e24S–e43S

    Article  CAS  Google Scholar 

  12. Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK (2016) Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 41(1):165–186

    Article  CAS  Google Scholar 

  13. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram. Ann Intern Med 119:874–881

    Article  CAS  Google Scholar 

  14. Fan J, John B, Tesdal E (2016) Evaluation of UFH dosing based on adjusted body weight in obese patients. Am J Health Syst Pharm 73:1512–1522

    Article  Google Scholar 

  15. Isherwood M, Murphy ML, Bingham AL, Siemianowski LA, Hunter K, Hollands JM (2017) Evaluation of safety and effectiveness of standardized anti-factor Xa-based unfractionated UFH protocols in obese versus non-obese patients. J Thromb Thrombolysis 43(4):476–483

    Article  CAS  Google Scholar 

  16. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA (1997) Relation between the time to achieve the lower limit of the aPTT therapeutic range and recurrent venous thromboembolism during UFH treatment for deep vein thrombosis. Arch Intern Med 157:2562–2568

    Article  CAS  Google Scholar 

  17. Hylek EM, Regan S, Henault LE et al (2003) Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 163:621–627

    Article  Google Scholar 

  18. Hosch LM, Breedlove EY, Scono LE, Knoderer CA (2017) Evaluation of an unfractionated UFH pharmacy dosing protocol for the treatment of venous thromboembolism in nonobese, obese, and severely obese patients. Ann Pharmacother 51(9):768–773

    Article  CAS  Google Scholar 

  19. Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747

    Article  Google Scholar 

  20. Spruill WJ, Wade WE, Huckaby WG, Leslie RB (2001) Achievement of anticoagulation by using a weight-based UFH dosing protocol for obese and nonobese patients. Am J Health- Syst Pharm 58:2143–2146

    Article  CAS  Google Scholar 

  21. Yee WP, Norton LL (1998) Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 55:159–162

    Article  CAS  Google Scholar 

  22. Hohner EM, Kruer RM, Gilmore VT, Streiff M, Gibbs H (2015) Unfractionated UFH dosing for therapeutic anticoagulation in critically ill obese adults. J Crit Care 30(2):395–399

    Article  CAS  Google Scholar 

  23. Gerlach AT, Folino J, Morris BN, Murphy CV, Stawicki SP, Cook CH (2013) Comparison of heparin dosing based on actual body weight in non-obese, obese and morbidly obese critically ill patients. Int J Crit Illn Inj Sci 3(3):195–199

    Article  Google Scholar 

  24. Shin S, Harthan EF (2015) Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patients: a retrospective chart review. Blood Coagul Fibrinolysis 26:655–660

    CAS  PubMed  Google Scholar 

Download references

Funding

None to disclose.

Author information

Authors and Affiliations

  1. Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA

    Alex M. Ebied, Tammy Li, Samantha F. Axelrod & Douglas J. Tam

  2. Data Management Analyst II, University of Florida College of Pharmacy, Gainesville, FL, USA

    Yiqing Chen

Authors
  1. Alex M. Ebied
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tammy Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samantha F. Axelrod
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Douglas J. Tam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yiqing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alex M. Ebied.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Additional informed consent was obtained from all individual participants for whom identifying information is included in this article

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ebied, A.M., Li, T., Axelrod, S.F. et al. Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels. J Thromb Thrombolysis 49, 206–213 (2020). https://doi.org/10.1007/s11239-019-01942-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-019-01942-6

Keywords

Search

Navigation